Literature DB >> 17972958

Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation.

K Hussein, O Bock, K Theophile, A Seegers, H Arps, O Basten, K-H Grips, J Franz-Werner, G Büsche, H Kreipe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17972958     DOI： 10.1038/sj.leu.2404993

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  16 in total

Review 1.  [Myeloproliferative neoplasms: histopathological and molecular pathological diagnosis].

Authors:  K Hussein; G Büsche; J Schlue; U Lehmann; H Kreipe
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

2.  JAK2 V617F mutation positive primary myelofibrosis with concomitant t(9;11;22)(q34;p15;q11.2) but no BCR/ABL fusion.

Authors:  Wing-Yan Au; Thomas S K Wan; Edmond S K Ma
Journal:  Int J Hematol       Date:  2013-02-07       Impact factor: 2.490

3.  Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia.

Authors:  You-Wen Qin; Yi-Ning Yang; Su Li; Chun Wang
Journal:  Indian J Hematol Blood Transfus       Date:  2014-04-11       Impact factor: 0.900

4.  Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.

Authors:  Craig R Soderquist; Mark D Ewalt; David R Czuchlewski; Julia T Geyer; Heesun J Rogers; Eric D Hsi; Sa A Wang; Carlos E Bueso-Ramos; Attilio Orazi; Daniel A Arber; Elizabeth O Hexner; Daria V Babushok; Adam Bagg
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

5.  Increased megakaryocytic proliferation, pro-platelet deposition and expression of fibrosis-associated factors in children with chronic myeloid leukaemia with bone marrow fibrosis.

Authors:  K Hussein; A Stucki-Koch; G Göhring; H Kreipe; M Suttorp
Journal:  Leukemia       Date:  2017-02-27       Impact factor: 11.528

6.  Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate.

Authors:  Yoo Jin Lee; Joon Ho Moon; Ho Cheol Shin; Jong Won Seo; Seo Ae Han; Sang Kyeong Seo; Sang Kyun Sohn
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

7.  Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutation.

Authors:  Weiyi Xu; Baode Chen; Xiangmin Tong
Journal:  Int J Hematol       Date:  2013-11-30       Impact factor: 2.490

8.  Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.

Authors:  C Walz; N C P Cross; R A Van Etten; A Reiter
Journal:  Leukemia       Date:  2008-06-05       Impact factor: 11.528

Review 9.  Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review.

Authors:  Yanhua Yue; Wei Wei; Yanting Guo; Fei Wang; Weimin Dong; Yue Liu; Yan Lin; Yang Cao; Weiying Gu
Journal:  Am J Case Rep       Date:  2020-10-06

Review 10.  [Chronic myeloid neoplasms. Diagnostic criteria and current therapeutic concepts].

Authors:  A H Schmitt-Graeff
Journal:  Pathologe       Date:  2010-02       Impact factor: 1.011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.